A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction

Status:
Completed

Trial end date:
2015-02-05

Target enrollment:

Participant gender:

This study will evaluate the safety and efficacy of AGN-195263 compared to vehicle in patients with meibomian gland dysfunction (MGD) in the eyelids.

Phase 2

Allergan